共 320 条
[1]
Ferlay JSI(2014)Cancer incidence and mortality worldwide: IARC Sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-386
[2]
Ervik M(2007)Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial J Clin Oncol 25 4224-4230
[3]
Dikshit R(2008)Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2006-2012
[4]
Eser S(2007)Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group J Clin Oncol 25 4217-4223
[5]
Mathers C(2006)FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) Br J Cancer 94 798-805
[6]
Rebelo M(2004)Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers Clin Colorectal Cancer 4 46-50
[7]
Parkin DM(2007)Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 135-142
[8]
Forman D(2010)Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis Br J Cancer 102 987-994
[9]
Bray F(2010)Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) Lancet Oncol 11 853-860
[10]
Diaz-Rubio E(1998)CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein Br J Cancer 77 359-365